VLDLR and age-related macular degeneration: Although our study does not provide definitive proof of a causal link between dyslipidemia and AMD, it does support the relevance of the VLDLR KO mouse model of AMD to humans and raises the possibility that therapies that increase the supply of fatty acids through VLDL to the retina, or that may reduce the reliance on lipids as a fuel, could be relevant to the prevention and treatment of AMD.